We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer and Merck KGaA’s new immuno-oncology drug Bavencio, which won an FDA nod for Merkel cell carcinoma in March, is now approved in Europe to treat the aggressive type of skin cancer.